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ABSTRACT
The purpose of the study was to define a risk score for 1-year treatment-related mortality (TRM) in children
undergoing allogeneic stem cell transplantation as a basis for risk-adjusted outcome assessment. We analyzed
1364 consecutive stem cell transplants performed in 24 German and Austrian centers between 1998 and 2003.
Five well-established risk factors were tested by multivariate logistic regression for predictive power: patient
age, disease status, donor other than matched sibling donor, T cell depletion (TCD), and preceding stem cell
transplantation. The risk score was defined by rounding the parameter estimates of the significant risk factors
to the nearest integer. Crossvalidation was performed on the basis of 5 randomly extracted equal-sized parts
from the database. Additionally, the score was validated for different disease entities and for single centers.
Multivariate analysis revealed a significant correlation of TRM with 3 risk factors: age .10 years, advanced
disease, and alternative donor. The parameter estimates were 0.76 for age, 0.73 for disease status, and 0.97
for donor type. Rounding the estimates resulted in a scorewith 1 point for each risk factor.One-yearTRM (over-
all survival [OS]) were 5% (89%) with a score of 0, 18% (74%) with 1, 28% (54%) with 2, and 53% (27%) with
3 points. Crossvalidation showed stable results with a good correlation between predicted and observed mortal-
ity but moderate discrimination. The score seems to be a simple instrument to estimate the expected mortality
for each risk group and for each center.MeasuringTRMrisk-adjusted and the comparison between expected and
observed mortality may be an additional tool for outcome assessment in pediatric stem cell transplantation.
 2008 American Society for Blood and Marrow Transplantation
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During the last decade the need for continuous
quality control in health care has become a general
consensus. Many national authorities and healthcare
providers are recommending the implementation of
quality management systems in clinical programs
either by legislation or financial stimulation. Accredi-
tation programs for hospitals and special health
services, which have been developed primarily in
Anglo-American health systems, are now increasingly
being established in Europe [1,2]. Accreditation pro-
grams for stem cell transplant (SCT) units such as
FACT or JACIE are requiring the implementation ofa quality management system and compliance with
standards concerning structure and process and out-
come [3-5]. Obligatory outcome measurement is
mainly related to ‘‘technical excellence,’’ that is, the re-
sults of cell collection and cell processing procedures
[4]. However, with an increasing number of allogeneic
transplants performed worldwide because of both
a larger spectrum of patients eligible for SCT and an
incremental availability of volunteer donors, govern-
mental authorities, insurers, and patients are increas-
ingly expecting reliable clinical outcome data [6-8].
Additionally, the influence of center- and physician-
related factors on outcome in pediatric hemato-onco-
logy are currently being discussed to define optimized335
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process, and technical outcome of defined procedures
are relatively easy to evaluate, the clinical outcome may
be influenced by factors that are not associated with
quality of care such as different degrees of comorbid-
ities [13]. Patient-related outcome measurement—
survival and treatment-related mortality (TRM)—in
pediatric SCT patients with diverging expected sur-
vival rates—depending on underlying disease, patient
status, and transplant modalities—is additionally ham-
pered by relatively small patient numbers per center
per year [4,14]. As a consequence, an increase in
TRM per center does not necessarily mean a decrease
in quality, but may reflect a higher proportion of
patients at risk.
As shown in cardiac surgery and intensive care
medicine, risk scores designed to predict treatment
outcome may be a helpful tool not only for medical
decision making, but also for risk-adjusted clinical out-
come measurement [15-17].
In contrast to intensive care patients, patients
eligible for SCT are not severely ill at admission,
despite suffering from a potentially life-threatening
disease. Gratwohl and others [18] developed a highly
predictive score for Chronic myelogenous leukemia
[CML]-patients undergoing allogeneic SCT; how-
ever, this score is disease-specific, and CML is a rare
disease in pediatric patients. The most commonly
used risk score in hemato-oncology is the Charlson
index [19]. Modified for SCT patients by Sorror et al
[20], the score correlates linearly with TRM in adult
SCT. It is, however, ill-suited for pediatric patients
for 2 reasons: first, it focuses on comorbidities that
are characteristic of elderly patients (congestive heart
failure, liver cirrhosis, cerebrovascular disease, diabe-
tes); second, typically, children scheduled for SCT
do not have measurable organ dysfunction despite
a high toxic and infectious preload [19,20]. The only
pediatric risk score for TRM is based on clinical
parameters on day 17 after transplantation, and thus
may be influenced by procedure-related modalities
and clinical decisions [21].
To facilitate risk-adjusted outcome measurement
in pediatric SCT programs, we aimed to develop
a pediatric TRM risk score.
PATIENTS AND METHODS
Patients
The Pediatric Register for Stem Cell Transplanta-
tion (PRST) is collecting data from German and Aus-
trian pediatric transplant centers. Because transplant
modalities changed substantially in the early 1990s,
for example, HLA-typing and methods of T cell deple-
tion (TCD), and a minimum observation time of 1 year
was required, data from 1630 consecutive transplants
performed between January 1, 1998, and December 30,2003, were analyzed. In patients who received second
stem cell infusions within 60 days of the first trans-
plant, only the first transplant was included. Data for
221 transplants (206 patients) were not included in
the analysis because of missing data for 1 or more of
the selected risk factors. Patient and transplant charac-
teristics of the remaining 1364 transplants in 1291
patients are listed in Table 1. HLA typing strategies
varied between centers and over time, and the respec-
tive information was not part of the registry data.
Table 1 shows the degree of HLA match reported by
the different centers. The median observation time
was 1.9 years (range: 1.0-6.2). TRM was defined
according to the EBMT guidelines [22]. For nonma-
lignant diseases any death within the first year was con-
sidered transplant associated.
Selection of Risk Factors
Well-established significant risk factors were
selected with reference to published data: patient age,
hematopoietic malignancy, advanced disease, unrelated
or mismatched donor, TCD graft, and prior SCT
Table 1. Patient and Transplant Characteristics
Total number of transplants 1364
Year of transplant 1998-2003
Number of Transplants
per center
median 37
(range: 2-172)
Age at SCT median 8.7
(range: 0.3-26.2)
Underlying disease:
Acute leukemias 676
ALL 449
AML 207
AUL 20
Chronic leukemias 84
MDS 170
RA 52
RAEB 31
RAEB-T 36
JMML 51
Lymphoma 49
Rhabdomyosarcoma/neuroblastoma 8
Severe aplastic anemia 116
Genetic diseases 261
Donor:
Matched sibling donor 446
Identical family donor 54
Mismatched family donor 186
1-AG-mm 41
.1-AG.mm 145
Unrelated donor 678
1-AG-mm 116
.1-AG-mm 77
Type of graft:
Bone marrow 680
Peripheral blood stem cells (PBSC) 669
Bone marrow 1 PBSC 3
Cord blood 12
T cell depletion 428
Prior stem cell transplantation 73
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sion in acute leukemia and lymphoma and .chronic
phase I (CP1) in chronic leukemia. All parameters
were binary. In the first step, age was included as a con-
tinuous factor and was dichotomized in a second step.
Statistics
Statistical analysis was performed using SAS (ver.
9.1, SAS Institute Inc., Cary, NC). A 2-sided P-value
of \.05 was considered significant. The association
between the selected risk factors and the 1-year inci-
dence of TRM was analyzed univariately with chi-
square test and Fisher’s exact test, respectively. For
multivariate analysis, logistic regression was used. In
the initial model all 5 risk factors (without interactions)
were included. In the first step, age was a continuous
variable. The prognostic impact of age with a cutoff
point of 10 years (Figure 1), published in other studies,
was supported by our data, and for the remaining anal-
ysis age dichotomized in the age groups below and
above 10 years [31]. In the second step, nonsignificant
factors were excluded from the model. In addition to
logistic regression, a mixed model was performed,
including center as random effect. We also evaluated
the interactions among the significant predictors.
The discrimination of the model was studied by mea-
suring the area under the receiver operating character-
istic (ROC) curve [34]. An additive score was created
using the rounded parameter estimates of this final
model. The discrimination of the simplified model
using the score was also described with the area under
the ROC curve. For crossvalidation we randomly
extracted 5 equal-sized parts from the database [35].
The model-building procedure was repeated 5 times
using 4 parts of the sample as a development set and
the remaining part as the validation set. A similar ap-
proach was used by splitting the sample according to
transplant center. These crossvalidation procedure al-
lowed us to estimate the variability of prediction re-
sulting from the construction process of the
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 5 10 15 20
Age
T
R
M
 
%
 
according to logistic regression observed
Figure 1. Correlation of age at SCT with TRM: best cutoff at
10 years.prognostic score. We also looked at the homogeneity
of the parameter estimates across the model-building
processes. At this point, we examined whether round-
ing of the coefficients would influence the results. The
quality of prediction in the validation sets was assessed
by looking at the goodness-of-fit in terms of the P-
values for the Hosmer-Lemeshow tests. The median
number of transplants performed per center during
the study period was 37 (range: 2-172). For the cen-
ter-related analysis, centers with \50 transplants
within the 6-year study period were pooled in 1 group.
The ratio between the expected number of deaths as
predicted from the model and the number of observed
treatment-related deaths with the 95% confidence
interval was calculated for each center. In addition to
the incidence of 1 year TRM, overall mortality was
estimated for the different risk groups defined by the
final scores. This was done with Kaplan-Meier esti-
mates and log-rank test. In contrast to the analysis of
1-year TRM, the unit studied was the patient and
not the transplant.
Cumulative incidence of TRM more than 1 year
after transplant are given, taking into account the com-
peting risk of death because of relapse.
For 136 patients whose last documented clinical
follow-up examination was \1 year after transplant,
an update from the respective centers was obtained
by the PRST data center. Missing data: 221 (14%)
transplants were not included in the analysis because
of missing data for 1 or more of the selected risk
factors. The percentage of patients with missing data
did not exceed 10% in all but 2 centers (missing data
for 11 of 78 patients and 5 of 43 patients, respectively).
The risk factors—donor type and TCD—were
unknown in 37 (2%) and 217 (14%), respectively.
Apart from TCD, 1548 (98%) were evaluable for all
remaining risk factors.
RESULTS
At the time of analysis (February 2005) 812 of 1291
(63%) patients were alive, and 179 (14%) had died
from relapse. One-year TRM, defined as nonrelapse
mortality (NRM) within the first year after SCT,
occurred in 308 of 1364 (23%) transplants. The 1-
year TRM in transplants that were not included in
the analysis with missing data on the selected risk fac-
tors was not significantly different (40 of 221; 1-year
TRM 5 18%; P 5 .136).
The median time point of TRM was day 178
(range: 14 to 11778). TRM was 13% on day 1100
(177 deaths) and 23% 1 year after transplant. In 14
cases (1% of all transplants), the time point of NRM
was more than 1 year after transplant. The most fre-
quently reported cause of TRM was infection (10%),
followed by toxic complications (5%), GVHD (4%),
and rejection or graft failure (2%). One very late death
338 S. Matthes-Martin et al.was caused by secondary malignancy. In 17 cases, the
causes of TRM were not specified.
By univariate analysis, all factors except the prior
SCT correlated significantly with TRM. By multivar-
iate analysis, disease status, donor other than matched
sibling donor, and age remained significantly corre-
lated with TRM (Table 2). There was no evidence
that interactions between the significant parameters
were present (Table 3). The multivariate analyses
were repeated, including the 221 transplants, which
primarily had been excluded because of missing data
concerning TCD with similar results.
The parameter estimates were 0.73 for disease
status, 0.94 for donor type, and 0.76 for age,
respectively. Rounding these estimates to the nearest
integer resulted in a very simple scoring system assign-
ing 1 point to each risk factor. This simplification did
not reduce substantially the discriminative power of
the model: the area under the curve (AUC) for the
original (unrounded) was 0.674 and 0.664 if the param-
eter estimates are rounded to 1 decimal place and to
the nearest integer, respectively. Similar results were
seen in a mixed model including center as random ef-
fect (data not shown).
Consequently, the score was defined as the sum of
risk factors: 0 for #10 years, 1 for .10 years; 0 for
matched sibling donors; 1 for alternative donors;
0 for#CR2 (acute leukemia), CP1 (chronic leukemia),
or MDS and nonmalignant diseases, 1 for .CR2 or
.CP1 and nonremission, resulting in 4 risk groups
with a score from 0 (eg, infant with immunodeficiency
and matched sibling donor) to 3 (eg, adolescent with
ALL, CR3, and unrelated donor).
Fifteen percent (n 5 206) of the transplants had
a score of 0, 47% (n 5 646) of 1, 31% (n 5 420) of
2, and 7% (n 5 92) of 3 points. The score correlated
highly (P\ .001) with 1 year TRM and additionally
showed an inverse correlation with overall survival
(OS). One-year TRM was 5% (score 0), 18% (score
1), 28% (score 2), and 52% (score 3), respectively.
Kaplan-Meier estimates of OS were 89% (score 0),
74% (score 1), 54% (score 2), and 27% (score 3), re-
spectively (Figure 2).
The repeated model-building process during
crossvalidation gave very stable results. Age, donor
type, and disease status had a significant impact on1-year TRM in each subpopulation. None of the
remaining parameters had a significant impact.
Rounding the parameter estimates to the nearest inte-
ger yielded the same scoring system in each subpopu-
lation. The predictive performance of the score in the
training data sets (used for model building) and the test
data sets were similar with an average AUC of 0.674
(training data sets) and 0.673 (test data sets) (Table
4). Similar results were obtained if crossvalidation
was done according to transplant center.
There was substantial variation concerning the
distribution of risk groups and TRM in the different
centers: the percentage of transplants with a score of
0 varied between 11% and 23% and with a score of 3
between 2% and 19%, respectively, and consequently,
the TRM in single centers varied between 11% and
34%. However, the score-based calculation of the ex-
pected TRM per center showed a strong correlation
with the observed TRM (Figure 3). The ratio between
expected and observed treatment-related deaths
ranged between 0.6 and 1.5.
As the diagnosis of the majority of pediatric
patients receiving allogeneic SCT is acute leukemia,
the score was additionally evaluated separately for pa-
tients with chronic leukemia (score 0-3), severe aplastic
anemia (AA) and inborn errors (score 0-2). TRM was
2%, 21%, 35%, and 50% in patients with chronic leu-
kemia, 3%, 15%, and 27% in patients with severe AA,
and 9%, 19%, and 36% in patients with inborn errors.
DISCUSSION
Clinical outcome has been defined by A. Donabe-
dian [5] as ‘‘changes (desirable or undesirable) in indi-
viduals and populations that can be attributed to health
care,’’ and comprises various clinical, functional,
psychologic, and social aspects. To confine outcome
measurement to therapy-related mortality and survival
is a considerable simplification. It may be justified,
however, in therapies for lethal or potentially lethal
diseases, such as conditions requiring intensive care
or oncologic diseases and therapies with relevant
therapy associated mortality such as cardiac surgery
or allogeneic SCT [36,37]. To define outcome by sur-
vival or therapy-related mortality may be a first step inTable 2. Correlation between Tested Risk Factors and TRM: By Multivariate Analysis
Risk Factor OR 95% Confidence Limits P-Value
Age at SCT .10 versus #10 years 2.3 1.8 3.1 \.001
Underlying disease Malignant versus Nonmalignant 1.0 0.7 1.3 .786
Donor type Alternative donor versus MSD 2.7 1.9 3.8 \.001
T cell depletion T cell depleted graft versus Treplete graft 1.3 0.9 1.7 .113
Number of SCT 2nd SCT versus 1st SCT 1.2 0.7 1.9 .479
Remission status .CR2 or CP1 or NR versus others 1.8 1.3 2.6 \.001
OR indicates odds ratio; SCT, stem cell transplant; MSD, matched sibling donor; TRM, treatment-related mortality.
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A: The 1-Year TRM Rates for All Unique Profiles (ie, Possible Combinations of the Risk Factors) of the Final Model
1-Year TRM
Pts. n %
Score 0 All 206 11 5
age\10 Matched Sibling Donor No Advanced Disease 206 11 5
Score 1 All 646 114 18
age\10 Matched sibling donor Advanced disease 28 4 14
Alternative donor No advanced disease 440 83 19
age .10 Matched sibling donor No advanced disease 178 27 15
Score 2 All 420 117 28
age\10 Alternative donor Advanced disease 99 23 23
age .10 Matched sibling donor Advanced disease 37 9 24
Alternative donor No advanced disease 284 85 30
Score 3 All 92 48 52
Age .10 Alternative donor Advanced disease 92 48 52
B: The Logistic Model Including All 2-Way Interactions of the Different Risk Factors
Analysis of Maximum Likelihood Estimates
Parameter DF Estimate Standard Error Wald Chi-Square Pr . Chi Sq
Intercept 1 22.7362 0.2763 98.1030 \0.0001
Age 1 0.9460 0.3322 8.1085 0.0044
Donor 1 1.2543 0.2967 17.8665 \0.0001
Disease 1 0.3966 0.4414 0.8074 0.3689
Age and donor 1 20.2890 0.3619 0.6377 0.4245
Age and disease 1 0.4731 0.3307 2.0460 0.1526
Donor and disease 1 20.0247 0.4131 0.0036 0.9523
TRM indicates treatment-related mortality.quality control, followed by more sophisticated out-
come measurements in the surviving patients [5,9].
To measure risk-adjusted outcomes, we aimed to
define a pediatric risk score on the basis of different
published risk factors. To restrict the candidate risk
factors to ‘‘biologic,’’ patient-, and donor-related con-
ditions should allow risk-adjusted outcome assess-
ment, not only in single transplant units but also
concerning different transplant protocols, for example,
reduced versus myeloablative conditioning.
Univariate analysis confirmed the correlation of
TRM with all previously published risk factors, except
second SCT. The finding that second transplants were
not associated with a significantly increased TRM may
be because of the fact that these were usually per-
formed with a nonmyeloablative conditioning regimen
[38-40]. Patient age, disease status, and donor status
remained significantly correlated with TRM in multi-
variate analysis and assigning 1 point to each risk factor
resulted in a risk score that was highly correlated with
TRM and overall mortality in the whole patient
cohort, within the different disease entities and for
each center.
As the score was developed and validated on the
basis of registry data, for 13% of the transplants data,
for at least 1 of the selected risk factors, was missing.
As the exclusion of this patient cohort for the multivar-
iate analysis might implicate a selection bias, thesetransplants were analyzed separately, and no signifi-
cant differences concerning overall TRM and correla-
tion of the final score with TRM could be detected.
The fact that HLA-typing strategies varied be-
tween centers and over time is 1 limitation of the study.
However, one could argue that the quality of HLA
typing (as part of the overall quality of care) has an
impact on TRM, and centers performing HLA class
I and class II high-resolution typing might have a lower
risk-adjusted TRM.
A substantial number of patients were lost to follow-
up after the first year after SCT. Although the low num-
ber of reported nonrelapse deaths more than 1 year after
SCT (1% in our study) is in concordance with other
published data, a higher incidence of very late deaths
related to chronic GVHD (cGVHD), infections, or
secondary malignancies cannot be excluded [41].
Another limitation of the score is the fact that
validation was performed on a regional European data-
base with comparable structures in pediatric transplant
centers and comparable treatment protocols, and thus
may not be applicable globally.
Finally, the validity of any TRM risk score has its
expiration date because of changes in indications for
allogeneic SCT, and in transplant modalities and peri-
odical revalidation is requisite.
The fact that only 3 risk factors were able to pre-
dict the risk of TRM is somewhat surprising. Disease
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Figure 2. Kaplan-Meier estimate of 1-year TRM and overall mortality. Kaplan-Meier estimate of 1-year TRM (black) and overall mortality
(gray) as stratified by the TRM risk score. Overall P-value for the ordinal score\.001 as well as for the pairwise comparison; the respective hazard
ratio (HR) with 95% confidence interval (95%CI).status reflects a number of additional risk factors for
TRM: comorbidity in pediatric SCT patients is mainly
the result of treatment-related toxic and infectious
preload and advanced disease. In most cases, advanced
disease status correlates with multiple cytostatic thera-
pies and, consequently, an increased toxic preload on 1
hand and a prolonged period of severe immunosup-
pression and infections on the other hand [31,42].
Concerning the donor status we defined the lack of
a matched sibling donor globally as a potential risk
factor without differentiating between matched and
mismatched unrelated donors and haploidentical fam-
ily donors for various reasons: (1) although results of
unrelated donor transplantations have improved over
time, this is mainly true for prospective protocols onselected patient cohorts [43]. (2) Typing strategies
are neither uniform in our multicenter retrospective
study cohort nor are they in different centers or treat-
ment protocols. (3) Alternative donor transplants for
pediatric patients are usually considered for high-risk
patients only [44]. (4) Patients with alternative donors
receive a more intensified pre- and posttransplant
immunosuppression in most cases, and they have an
increased risk for GVHD, both resulting in an in-
creased risk for late infectious complications. Infec-
tions with or without GVHD are the most common
causes of death following SCT in children [24,45].
Because of the limited number of analyzed param-
eters, the model and the resulted score were very sim-
ple. The results of the crossvalidation also suggest thatTable 4. Results of the Crossvalidation
ALL Part 1 Part 2 Part 3 Part 4 Part 5
Estimate P-Value Estimate P-Value Estimate P-Value Estimate P-Value Estimate P-Value Estimate P-Value
Model 1: All parameters
Age 0.85 \.0001 0.77 \.001 0.98 \.001 0.87 \.001 0.94 \.001 0.69 \.001
Disease 20.05 .786 0.03 .894 20.02 .931 20.07 .727 20.07 .719 20.11 .573
Donor 1.00 \.0001 0.85 \.001 1.07 \.001 0.94 \.001 1.04 \.001 1.09 \.001
Graft 0.24 .113 0.25 .130 0.32 .056 0.20 .228 0.18 .288 0.24 .152
No SCT 0.17 .479 0.17 .503 0.26 .314 0.13 .612 0.09 .739 0.17 .518
Remission 0.61 .000 0.67 \.001 0.58 \.001 0.56 \.001 0.63 \.001 0.62 \.001
Model 2: Significant parameters only
Age 0.83 \.001 0.76 \.001 0.95 \.001 0.85 \.001 0.92 \.001 0.66 \.001
Donor 1.06 \.001 0.94 \.001 1.16 \.001 1.00 \.001 1.08 \.001 1.15 \.001
Remission 0.65 \.001 0.73 \.001 0.64 \.001 0.58 \.001 0.64 \.001 0.63 \.001
The model-building procedure repeated 5 times using 4 parts of the sample as a development set and 1 as validation set for all selected risk factors
(Model 1) and for those risk factors that are significantly correlated with TRM by multivariate analysis (Model 2).
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Figure 3. Score-based expected and observed 1-year TRM per center. Score-based expected and observed 1-year TRM with 95% confidence
interval. Fourteen centers with\50 transplants during the study period are pooled in one group.the amount of overfitting was small; thus, the discrim-
inating power of the score was likely to be similar in an
independent data set [46].
In terms of quality management and continuous
quality control within a single transplant center, risk-
adjusted TRM can be visualized continually using
the variable life-adjusted display (VLAD), first de-
scribed by Lovegrove et al [47] and others for cardiac
surgery. The VLAD illustrates the cumulative sum of
the difference between the expected and the observed
mortality continuously in a graph. The plot descends
(in the case of death) or ascends (in the case of survival)
according to the estimated probability. An example of
VLAD for TRM in a single pediatric SCT center is
shown in Figure 4.
Measuring risk-adjusted outcome permits to
detect variations in outcome not only in a single center,
but also between different centers and different treat-ment modalities. The comparison between expected
and observed mortality may be—among others—
a useful tool for outcome control. The analysis of
variations in clinical outcome facilitates the detection
of hidden errors and, more importantly, of variations
in procedures and standards that are associated with
an improved outcome [48-50]. ‘‘The real break-
through in quality assessment will come as a by-prod-
uct of research in the relationship between strategies of
care and outcome’’ (A. Donabedian) [51].
In addition, the TRM risk score correlated with
overall mortality, that is, TRM plus mortality because
of the underlying disease. This was mainly because: (1)
the maximum score for patients with nonmalignant
diseases was 2, (2) 1 point was assigned to transplants
for advanced disease, which per se have a higher
relapse incidence [31,52]. As a result, besides being
an instrument for quality control, the score may-1
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Figure 4.Variable life-adjusted display on the basis of the risk score. Example of VLAD (variable life-adjusted display) in 1 center illustrating the
cumulative sum (y-axis) of the difference between the expected and the observed mortality continuously during a 2-year period. (x-axis: number of
consecutive patients).
342 S. Matthes-Martin et al.provide pediatric SCT teams with a more realistic es-
timate of survival probabilities and thus help in clinical
decision making.
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